March 2020 - MiraVista Diagnostics

MiraVista COVID-19 Announcement

by Site Strategics | Mar 18, 2020 | News

MiraVista is open and continues to provide critical diagnostic testing despite the impact COVID-19 has had on staffing. The health and welfare of our team is of critical importance. To limit the opportunity of exposure to COVID-19 for our entire team, MiraVista will...

MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC)

by Site Strategics | Mar 2, 2020 | News

In compliance with the National Institutes of Health Office of Science Policy (NIH OSP), MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC) to review, approve and confirm that the company’s research involving recombinant/synthetic DNA...

Only Available at MiraVista Diagnostics: MycoMEIA® Aspergillus Galf Urine EIA
MiraVista Diagnostics now offers MycoMEIA® Aspergillus Galf Urine EIA, a urine-based antigen assay that complements serum galactomannan (GM) testing and may improve diagnostic confidence for invasive aspergillosis (IA).

Learn More

MiraVista COVID-19 Announcement

MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC)

Recent Posts

Archives

Categories

Meta